Changes after publication

Changes after publication

February 2014: implementation section updated to clarify that rituximab is recommended as an option for treating relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. Additional minor maintenance update also carried out.

March 2012: minor maintenance